• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Hess, G.
    Dreyling, M.
    Oberic, L.
    Gine, E.
    Zinzani, P. L.
    Linton, Kim M
    Vilmar, A.
    Jerkeman, M.
    Chen, J. M. H.
    Ohler, A.
    Stilgenbauer, S.
    Thieblemont, C.
    Lambert, J.
    Zilioli, V. R.
    Sancho, J. M.
    Ubieto, A. J.
    Fischer, L.
    Eyre, T. A.
    Keeping, S.
    Park, J. E.
    Wu, J. J.
    Siddiqi, R.
    Reitan, J.
    Wade, S.
    Salles, G.
    Show allShow less
    Affiliation
    Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center, University Medical School of the Johannes Gutenberg-University, Mainz, Germany
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6-20.0) in the overall cohort, 5.5 months (95% CI 3.9-8.2) in 91 patients without post-BTKi therapy, and 23.8 months (95% CI 18.9-30.1) in 149 patients who received post-BTKi therapy (excluding chimeric antigen receptor T-cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post-BTKi therapy, with lenalidomide-containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post-BTKi therapy was 9.7 months (95% CI 6.3-12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.
    Citation
    Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. British journal of haematology. 2022 Oct 18. PubMed PMID: 36257914. Epub 2022/10/19. eng.
    Journal
    British Journal of Haematology
    URI
    http://hdl.handle.net/10541/625728
    DOI
    10.1111/bjh.18519
    PubMed ID
    36257914
    Additional Links
    https://dx.doi.org/10.1111/bjh.18519
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1111/bjh.18519
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
    • Authors: Burkart M, Karmali R
    • Issue date: 2022 Mar 1
    • Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance.
    • Authors: Liu S, Yang P, Wang L, Li C, Zhang W, Wang J, Jing H
    • Issue date: 2022 Oct
    • Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
    • Authors: Petersohn S, Salles G, Wang M, Wu J, Wade SW, Simons CL, Bennison C, Siddiqi R, Peng W, Kloos I, Castaigne G, Hess G
    • Issue date: 2022 Jan-Dec
    • Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    • Authors: Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM
    • Issue date: 2023 Jan 20
    • MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress).
    • Authors: Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, Jurczak W, Wang Y, Cheah CY, Gandhi M, Chay C, Sharman J, Andorsky DJ, Song Y, Stark A, Muthig V, Wang ML
    • Issue date: 2022 Oct
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.